Your gateway to a free society
Article
Amid Saber-Rattling, Iran Touts Economic Benefits To West If Nuclear Deal Reached
Amid Saber-Rattling, Iran Touts Economic Benefits To West If Nuclear Deal Reached
Days ahead of another round of talks with US negotiators -- and on the heels of more saber-rattling by the Trump administration -- Iran is touting the potential mutual economic benefits of a deal that would terminate the West's long-running sanctions regime against the second-largest and second-most-populous country in the Middle East.
"For the sake of an agreement's durability, it is essential that the U.S. also benefits in areas with high and quick economic returns," said Iranian Deputy Director for...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Apr 16, 2026 / Tyler Durden
Hegseth: Hormuz Blockade Stays "As Long As It Takes" - Ships Now Fair Game For Search & Seizure
Hegseth: Hormuz Blockade Stays "As Long As It Takes" - Ships Now Fair Game For Search & Seizure
Summary
US Navy: vessels seeking entry into Hormuz Strait now fair game for boarding, search, and outright seizure - including for suspicion of 'contraband'.
Hegseth: US forces are ready to restart combat if Iran doesn’t agree to a deal & strait blockade to continue for as long as it takes. Already 13 ships have been turned around.
Iran's parliament speaker Mohammad Bagher Qalibaf calls ceasefire in Lebanon "as important as a ceasefire in Iran."
Heavy Israeli bombardment of...
Read more
Apr 15, 2026 / Tyler Durden
US Prosecutors Make Surprise Visit To Fed HQ Renovation Project
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound).
Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug."
Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more
support
If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.
Support the liberty movement
Want to get in touch?